01966nas a2200421   4500000000100000008004100001260001300042653001400055653001300069653001600082653003700098653005200135653001000187653001300197653002100210653000900231653002000240653000900260653001100269653002100280653002900301653001200330653001800342653001300360653001400373653001700387653000900404653001600413653002200429100001500451700001200466245003600478300002100514490000800535050001800543520096900561022001401530       2004                            d  c2004 Dec10aArthritis10aCicatrix10aClofazimine10aDose-Response Relationship, Drug10aDrug-Related Side Effects and Adverse Reactions10aEdema10aErythema10aErythema Nodosum10aFoot10aGlucocorticoids10aHand10aHumans10aHypersensitivity10aImmunosuppressive Agents10aleprosy10aLymphadenitis10aNeuritis10aParalysis10aPrednisolone10aSkin10aThalidomide10aTreatment Outcome1 aGanapati R1 aPai V V00aReactions and their management.  a688-90, 692, 6940 v102  aGANAPATI 20043 a<p>The uneventful response to chemotherapy in leprosy is marked by clinically disturbing episodes encountered in 20-30% of patients and these phenomena are called "reactions". Generally they are classified as reversal reaction (type-1) and erythema nodosum leprosum (type-2). The cutaneous menifestations are: (1) Type-2 reactions in LL, BL types constituting erythema nodosum leprosum, erythema multiforme, erythema necroticans, subcutaneous nodules, lepromatous exacerbation. (2) Type-1 reactions in borderline and tuberculoid leprosy. The other manifestations include: Acute neuritis, lymphadenitis, arthritis, oedema of the hands and feet, ocular lesions, etc. Sequelae of reactions are: Paralytic deformities, non-paralytic deformities, extensive scarring and renal damage. A simple guideline to identify the risk-prone cases has been narrated. Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes.</p>  a0019-5847